Skip to main content
Erschienen in: Journal of General Internal Medicine 11/2020

04.08.2020 | Original Research

Medication Utilization for Alcohol Use Disorder in a Commercially Insured Population

verfasst von: Haiden A. Huskamp, Ph.D., Sharon Reif, Ph.D., Shelly F. Greenfield, M.D., M.P.H., Sharon-Lise T. Normand, Ph.D., Alisa B. Busch, M.D., M.S.

Erschienen in: Journal of General Internal Medicine | Ausgabe 11/2020

Einloggen, um Zugang zu erhalten

Abstract

Objective

Examine patterns of alcohol use disorder (AUD) medication use and identify factors associated with prescription fill among commercially insured individuals with an index AUD visit.

Design

Using 2008–2018 claims data from a large national insurer, estimate days to first AUD medication using cause-specific hazards approach to account for competing risk of benefits loss.

Participants

Aged 17–64 with ≥ 1 AUD visit.

Main Measure

Days to AUD medication fill.

Key Results

A total of 13.3% of the 151,128 with an index visit filled an AUD prescription after that visit, while 69.8% lost benefits before filling and 17.0% remained enrolled but did not fill (median days observed = 305). Almost half (46.3%) of those who filled a prescription received substance use disorder (SUD) inpatient care within 7 days before the fill, and 63.4% received SUD outpatient care. Likelihood of medication use was higher for those aged 26–35, 36–45, and 46–55 years relative to 56–64 years (e.g., 26–35: hazard ratio = 1.29 [95% confidence interval 1.23–1.36]); those diagnosed with moderate/severe AUD (2.05 [1.98–2.12]), co-occurring opioid use disorder (OUD) (1.33 [1.26–1.39]), or severe mental illness (1.31 [1.27–1.35]); those with a chronic alcohol-related diagnosis (1.08 [1.04–1.12]); and those whose index visit was in an inpatient/emergency department (1.27 [1.23–1.31]) or intermediate care setting (1.13 [1.07–1.20]) relative to outpatient. Likelihood of use was higher in later years relative to 2008 (e.g., 2018:2.02 [1.89–2.15]) and higher for those who received the majority of AUD care in a practice with a psychiatrist/addiction medicine specialist (1.13 [1.10–1.16]). Likelihood of use was lower for those diagnosed with a SUD other than AUD or OUD (0.88 [0.85–0.92]), those with an acute alcohol-related condition (0.79 [0.75–0.84]), and males (0.71 [0.69–0.73]).

Conclusions

While AUD medication use increased and was more common among individuals with greater severity, few patients who could benefit from medications are using them. More efforts are needed to identify and treat individuals in non-acute care settings earlier in their course of AUD.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Substance Abuse and Mental Health Services Administration. Key Substance Use and Mental Health Indicators in the United States: Results from the 2018 National Survey on Drug Use and Health. HHS Publication No. PEP19-5068, NSDUH Series H-54. Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. Available at: https://www.samhsa.gov/data/. Accessed January 13, 2020. Substance Abuse and Mental Health Services Administration. Key Substance Use and Mental Health Indicators in the United States: Results from the 2018 National Survey on Drug Use and Health. HHS Publication No. PEP19-5068, NSDUH Series H-54. Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. Available at: https://​www.​samhsa.​gov/​data/​. Accessed January 13, 2020.
2.
Zurück zum Zitat Centers for Disease Control and Prevention. Alcohol and Public Health: Alcohol-Related Disease Impact (ARDI) – Average for United States 2006 2010 Alcohol-Attributable Deaths Due to Excessive Alcohol Use. Available at: www.cdc.gov/ARDI. Accessed September 23, 2019. Centers for Disease Control and Prevention. Alcohol and Public Health: Alcohol-Related Disease Impact (ARDI) – Average for United States 2006 2010 Alcohol-Attributable Deaths Due to Excessive Alcohol Use. Available at: www.​cdc.​gov/​ARDI. Accessed September 23, 2019.
4.
Zurück zum Zitat Knudsen HK, Abraham AJ, Roman PM. Adoption and implementation of medications in addiction treatment programs. J Addict Med. 2011;5(1):21-27.CrossRef Knudsen HK, Abraham AJ, Roman PM. Adoption and implementation of medications in addiction treatment programs. J Addict Med. 2011;5(1):21-27.CrossRef
5.
Zurück zum Zitat Iheanacho T, Issa M, Marienfeld C, Rosenheck R. Use of naltrexone for alcohol use disorders in the Veterans' Health Administration: a national study. Drug Alcohol Depend. 2013;132(1-2):122-126CrossRef Iheanacho T, Issa M, Marienfeld C, Rosenheck R. Use of naltrexone for alcohol use disorders in the Veterans' Health Administration: a national study. Drug Alcohol Depend. 2013;132(1-2):122-126CrossRef
6.
Zurück zum Zitat Mark TL, Kassed CA, Vandivort-Warren R, Levit KR, Kranzler HR. Alcohol and opioid dependence medications: prescription trends, overall and by physician specialty. Drug Alcohol Depend. 2009;99(1-3):345-349.CrossRef Mark TL, Kassed CA, Vandivort-Warren R, Levit KR, Kranzler HR. Alcohol and opioid dependence medications: prescription trends, overall and by physician specialty. Drug Alcohol Depend. 2009;99(1-3):345-349.CrossRef
7.
Zurück zum Zitat Rieckmann T, Muench J, McBurnie MA, et al. Medication-assisted treatment for substance use disorders within a national community health center research network. Subst Abus. 2016;37(4):625-634CrossRef Rieckmann T, Muench J, McBurnie MA, et al. Medication-assisted treatment for substance use disorders within a national community health center research network. Subst Abus. 2016;37(4):625-634CrossRef
8.
Zurück zum Zitat Harris AH, Oliva E, Bowe T, Humphreys KN, Kivlahan DR, Trafton JA. Pharmacotherapy of alcohol use disorders by the Veterans Health Administration: patterns of receipt and persistence. Psychiatr Serv. 2012;63(7):679-685CrossRef Harris AH, Oliva E, Bowe T, Humphreys KN, Kivlahan DR, Trafton JA. Pharmacotherapy of alcohol use disorders by the Veterans Health Administration: patterns of receipt and persistence. Psychiatr Serv. 2012;63(7):679-685CrossRef
9.
Zurück zum Zitat Knudsen HK, Roman PM. Service delivery and pharmacotherapy for alcohol use disorder in the era of health reform: Data from a national sample of treatment organizations. Subst Abus. 2016;37(1):230-237CrossRef Knudsen HK, Roman PM. Service delivery and pharmacotherapy for alcohol use disorder in the era of health reform: Data from a national sample of treatment organizations. Subst Abus. 2016;37(1):230-237CrossRef
10.
Zurück zum Zitat Harris AH, Kivlahan DR, Bowe T, Humphreys KN. Pharmacotherapy of alcohol use disorders in the Veterans Health Administration. Psychiatr Serv. 2010; 61(4): 392-8CrossRef Harris AH, Kivlahan DR, Bowe T, Humphreys KN. Pharmacotherapy of alcohol use disorders in the Veterans Health Administration. Psychiatr Serv. 2010; 61(4): 392-8CrossRef
11.
Zurück zum Zitat Mark TL, Kranzler HR, Song X, Bransberger P, Poole VH, Crosse S. Physician’s opinions about medications to treat alcoholism. Addiction. 2003; 98(5): 617-26.CrossRef Mark TL, Kranzler HR, Song X, Bransberger P, Poole VH, Crosse S. Physician’s opinions about medications to treat alcoholism. Addiction. 2003; 98(5): 617-26.CrossRef
12.
Zurück zum Zitat Huskamp HA, Riedel LE, Barry CL, Busch AB. Coverage of medications that treat opioid use disorder and opioids for pain management in Marketplace plans. Med Care. 2018;56(6):505-509.CrossRef Huskamp HA, Riedel LE, Barry CL, Busch AB. Coverage of medications that treat opioid use disorder and opioids for pain management in Marketplace plans. Med Care. 2018;56(6):505-509.CrossRef
13.
Zurück zum Zitat Reif S, Horgan CM, Hodgkin D, Matteucci AM, Creedon TB, Stewart MT. Access to Addiction Pharmacotherapy in Private Health Plans. J Subst Abuse Treat. 2016;66:23-29.CrossRef Reif S, Horgan CM, Hodgkin D, Matteucci AM, Creedon TB, Stewart MT. Access to Addiction Pharmacotherapy in Private Health Plans. J Subst Abuse Treat. 2016;66:23-29.CrossRef
14.
Zurück zum Zitat Horgan CM, Reif S, Hodgkin D, Garnick DW, Merrick EL. Availability of addiction medications in private health plans. J Subst Abuse Treat. 2008;34(2):147-156.CrossRef Horgan CM, Reif S, Hodgkin D, Garnick DW, Merrick EL. Availability of addiction medications in private health plans. J Subst Abuse Treat. 2008;34(2):147-156.CrossRef
15.
Zurück zum Zitat Harris AHS, Ellerbe L, Reeder RN, et al. Pharmacotherapy for alcohol dependence: perceived treatment barriers and action strategies among Veterans Health Administration service providers. Psychol Serv. 2013; 10(4): 410-419.CrossRef Harris AHS, Ellerbe L, Reeder RN, et al. Pharmacotherapy for alcohol dependence: perceived treatment barriers and action strategies among Veterans Health Administration service providers. Psychol Serv. 2013; 10(4): 410-419.CrossRef
16.
Zurück zum Zitat Abraham AJ, Ducharme LJ, Roman PM. Counselor attitudes toward pharmacotherapies for alcohol dependence. J Stud Alcohol Drugs. 2009; 70(4): 628-35.CrossRef Abraham AJ, Ducharme LJ, Roman PM. Counselor attitudes toward pharmacotherapies for alcohol dependence. J Stud Alcohol Drugs. 2009; 70(4): 628-35.CrossRef
17.
Zurück zum Zitat Hoge MA, Stuart GW, Morris J, Flaherty MT, Paris M, Jr., Goplerud E. Mental health and addiction workforce development: federal leadership is needed to address the growing crisis. Health Aff (Millwood). 2013;32(11):2005-2012.CrossRef Hoge MA, Stuart GW, Morris J, Flaherty MT, Paris M, Jr., Goplerud E. Mental health and addiction workforce development: federal leadership is needed to address the growing crisis. Health Aff (Millwood). 2013;32(11):2005-2012.CrossRef
19.
Zurück zum Zitat Thomas CP, Ritter GA, Harris AHS, Garnick DW, Freedman KI, Herbert B. Applying American Society of Addiction Medicine Performance Measures in Commercial Health Insurance and Services Data. J Addict Med. 2018;12(4):287-294.CrossRef Thomas CP, Ritter GA, Harris AHS, Garnick DW, Freedman KI, Herbert B. Applying American Society of Addiction Medicine Performance Measures in Commercial Health Insurance and Services Data. J Addict Med. 2018;12(4):287-294.CrossRef
20.
Zurück zum Zitat Paparrigopoulos T, Tzavellas E, Karaiskos D, Kourlaba G, Liappas I. Treatment of alcohol dependence with low-dose topiramate: an open-label controlled study. BMC Psychiatry. 2011;11:41.CrossRef Paparrigopoulos T, Tzavellas E, Karaiskos D, Kourlaba G, Liappas I. Treatment of alcohol dependence with low-dose topiramate: an open-label controlled study. BMC Psychiatry. 2011;11:41.CrossRef
21.
Zurück zum Zitat Johnson BA, Rosenthal N, Capece JA, et al. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA. 2007;298(14):1641-1651.CrossRef Johnson BA, Rosenthal N, Capece JA, et al. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA. 2007;298(14):1641-1651.CrossRef
24.
Zurück zum Zitat Kaner EF, Beyer FR, Muirhead C, et al. Effectiveness of brief alcohol interventions in primary care populations. Cochrane Database Syst Rev. 2018;2:CD004148.PubMed Kaner EF, Beyer FR, Muirhead C, et al. Effectiveness of brief alcohol interventions in primary care populations. Cochrane Database Syst Rev. 2018;2:CD004148.PubMed
25.
Zurück zum Zitat O'Connor EA, Perdue LA, Senger CA, et al. Screening and Behavioral Counseling Interventions to Reduce Unhealthy Alcohol Use in Adolescents and Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2018;320(18):1910-1928.CrossRef O'Connor EA, Perdue LA, Senger CA, et al. Screening and Behavioral Counseling Interventions to Reduce Unhealthy Alcohol Use in Adolescents and Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2018;320(18):1910-1928.CrossRef
26.
Zurück zum Zitat Curry SJ, Krist AH, Owens DK, et al. Screening and Behavioral Counseling Interventions to Reduce Unhealthy Alcohol Use in Adolescents and Adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2018;320(18):1899-1909.CrossRef Curry SJ, Krist AH, Owens DK, et al. Screening and Behavioral Counseling Interventions to Reduce Unhealthy Alcohol Use in Adolescents and Adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2018;320(18):1899-1909.CrossRef
28.
Zurück zum Zitat Greenfield SF, Pettinati HM, O'Malley S, Randall PK, Randall CL. Gender differences in alcohol treatment: an analysis of outcome from the COMBINE study. Alcohol Clin Exp Res. 2010;34(10):1803-12.CrossRef Greenfield SF, Pettinati HM, O'Malley S, Randall PK, Randall CL. Gender differences in alcohol treatment: an analysis of outcome from the COMBINE study. Alcohol Clin Exp Res. 2010;34(10):1803-12.CrossRef
30.
Zurück zum Zitat Maisel NC, Blodgett JC, Wilbourne PL, Humphreys K, Finney JW. Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful? Addiction. 2013;108(2):275-293.CrossRef Maisel NC, Blodgett JC, Wilbourne PL, Humphreys K, Finney JW. Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful? Addiction. 2013;108(2):275-293.CrossRef
31.
Zurück zum Zitat Rosner S, Leucht S, Lehert P, Soyka M. Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes. J Psychopharmacol. 2008;22(1):11-23.CrossRef Rosner S, Leucht S, Lehert P, Soyka M. Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes. J Psychopharmacol. 2008;22(1):11-23.CrossRef
Metadaten
Titel
Medication Utilization for Alcohol Use Disorder in a Commercially Insured Population
verfasst von
Haiden A. Huskamp, Ph.D.
Sharon Reif, Ph.D.
Shelly F. Greenfield, M.D., M.P.H.
Sharon-Lise T. Normand, Ph.D.
Alisa B. Busch, M.D., M.S.
Publikationsdatum
04.08.2020
Verlag
Springer International Publishing
Erschienen in
Journal of General Internal Medicine / Ausgabe 11/2020
Print ISSN: 0884-8734
Elektronische ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-020-06073-w

Weitere Artikel der Ausgabe 11/2020

Journal of General Internal Medicine 11/2020 Zur Ausgabe

Healing Arts

Behind the Mask

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.